Relative survival among cancer survivors enrolled in private cancer insurance in Japan, using the internal insurance-enrolled population as the reference

以日本国内参保人群为参照,分析日本私人癌症保险参保癌症幸存者的相对生存率

阅读:1

Abstract

BACKGROUND: Limited data are available on relative survival (RS) among cancer survivors enrolled in private cancer insurance in Japan. Additionally, the incidence of second primary cancers or recurrences, as applicable, after a certain period remains unclear. METHODS: We analyzed 8,846 cancer survivors, including carcinoma in situ, aged 15-79 years, enrolled in private cancer insurance between April 2005 and September 2021, and diagnosed before April 2022. Using the entire insurance-enrolled population as the reference, we estimated sex- and age group-specific RS, conditional RS (CRS), and age-standardized RS (ASR) by cancer type. The cumulative incidence of second primary cancers or recurrences, as applicable, was calculated among cancer-free 3-, 4-, and 5-year survivors. RESULTS: Median ages at first diagnosis were 61.5 years for males and 55.0 years for females. Over median follow-up of 3.40 years, 1,772 deaths (45.4 per 1,000 person-years) occurred. The 5-year RS declined with age: 81.8% for males and 94.8% for females aged 15-39, but 68.5% and 71.8% for those aged 70-79. The 5-year CRS increased with time since diagnosis, exceeding 90% among 5-year survivors in all groups except males aged 70-79. Liver cancer survivors had the highest incidence of second primary cancers or recurrences, predominantly due to recurrences, even after 5 cancer-free years. CONCLUSION: We estimated sex- and age group-specific RS, CRS, and ASR by cancer type, and the incidence of second primary cancers or recurrences, using a database of private cancer insurance policyholders, though the findings may not be generalizable to the national population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。